This study investigates advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. The purpose of this study is to explore the safety and effects of an investigational medication called an antibody drug conjugate (ADC).
The study evaluates how well the investigational medication works in targeting and affecting cancer cells. It focuses on understanding its safety and effectiveness for participants with these advanced cancers.
- Who can participate: Participants must be 18 years or older with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. They should have measurable disease and an ECOG Performance status of 0-1.
- Study details: Participants will receive the investigational medication through an intravenous infusion.
How understandable was the trial content above?
Hard to understand
Easy to understand